fig5

Figure 5. Ivosidenib reduces the stemness of ovarian cancer cells. (A) Quantitative analysis of the mRNA levels of stemness-related genes, including ALDH1A1, CD44, BIM-1, and KLF-4 in SKOV3, CAOV3, OVCAR4, SKDDP, and SK-3rd treated with DMSO, 10 μM Ivosidenib, 10 μM cisplatin, or their combination for 72 h by qRT-PCR. Data are represented as mean ± SD of three biologically independent experiments. ns, not significant, *P <0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 using a one-way ANOVA followed by Tukey's post hoc test for multiple comparisons. (B) Representative images of ALDH1+ cells were analyzed using flow cytometry in SKOV3 cells treated with DMSO, 10 μM Ivosidenib, 10 μM cisplatin, or their combination for 72 h. DEAB was used as the negative control for ALDH1 activity. (C) The proportion of ALDH1+ cells was analyzed statistically in SKOV3, CAOV3, OVCAR4, SKDDP, and SK-3rd. Data are represented as mean ± SD of three biologically independent experiments. ns, not significant, *P <0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 using a one-way ANOVA followed by Tukey's post hoc test for multiple comparisons. (D) Representative images and statistical histograms of spheres generated by SKOV3, CAOV3, OVCAR4, SKDDP, and SK-3rd cells treated with DMSO or 10 μM Ivosidenib. Scale bar: 50 μm. *P <0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 using an unpaired Student's t-test.